logo

For the Inventor, By the Inventor

Muko, Japan

Mineo Niwa

This inventor holds 17 USPTO granted patents, plus 1 CIPO patent. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1988-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mineo Niwa. Retrieved from https://idiyas.com/inventor/mineo-niwa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 6

Forward Citations = 111(Granted Patents)


Location History:

  • Mukoo, JP (1988 - 1991)
  • Kyoto, JP (1994)
  • Muko, JP (1992 - 2001)
  • Mukou, JP (2002)

Company Filing History:

goldMedal17 out of 940 
 
Fujisawa Pharmaceutical Company, Ltd.
 patents

Years Active: 1988-2002

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 6403336 - Process for the production of &agr;-human atrial natriuretic polypeptide (2002-06-11),
2. 6197562 - L-sorbose dehydrogenase and novel L-sorbosone dehydrogenase obtained from gluconobacter oxydans T-100 (2001-03-06),
3. 5888786 - Method for producing 2-keto-L-gulonic acid (1999-03-30),
4. 5861292 - L-sorbose dehydrogenase and novel L-sorbosone dehydrogenase obtained (1999-01-19),
5. 5840533 - Tissue plasminogen activator (1998-11-24),
6. 5834263 - Method for producing 2-keto-L-gulonic acid (1998-11-10),
7. 5804429 - Cephalosporin C acylase (1998-09-08),
8. 5753481 - L-sorbose dehydrogenase and novel L-sorbosone dehydrogenase obtained (1998-05-19),
9. 5648250 - Tissue plasminogen activator (1997-07-15),
10. 5576183 - Monoclonal antibody recognizing FK506-binding protein, method for (1996-11-19),
11. 5532137 - Anti-FR-900506 substance antibodies and highly-sensitive enzyme (1996-07-02),
12. 5340725 - Expression vector for insulin-like growth factor I and method of (1994-08-23),
13. 5336613 - Cephalosporin C acylase (1994-08-09),
14. 5102985 - Process for the formation of intramolecular disulfide bridge in a (1992-04-07),
15. 5028531 - IGF-I fusion proteins; protection of IGF-I from degradation by host (1991-07-02),

Certainly! Here is the article about inventor Mineo Niwa:

Title: Mineo Niwa: Pioneering Innovations in the World of Inventions

Introduction:

Mineo Niwa is a visionary inventor whose passion for innovation and relentless pursuit of technological advancement have solidified his position as a trailblazer in the world of inventions. Hailing from Muko, Japan, Niwa has made significant contributions that continue to inspire future generations of inventors worldwide.

Latest Patents:

Niwa's latest patents showcase his ingenuity and creativity:

1. Process for the production of α-human atrial natriuretic polypeptide - DNA fragments containing a sequence encoding a protective peptide-fused α-hANP, vectors, and microorganisms for production.

2. L-sorbose dehydrogenase and novel L-sorbosone dehydrogenase - Enzymes derived from Gluconobacter oxydans T-100, used in the production of 2-keto-L-gulonic acid and L-ascorbic acid.

Career Highlights:

Niwa is a key figure at Fujisawa Pharmaceutical Company, Ltd., where he spearheads innovative projects and contributes to groundbreaking discoveries in the field of biotechnology. With a total of 17 patents to his name, Niwa's expertise and dedication have yielded remarkable advancements in the industry.

Collaborations:

Niwa collaborates closely with esteemed colleagues Yoshimasa Saito and Yoshinori Ishii, pooling their collective knowledge and skills to drive forward-thinking research and development initiatives. Together, they form a dynamic team that continues to push the boundaries of technological innovation.

Conclusion:

In conclusion, Mineo Niwa's unwavering commitment to innovation and his exceptional contributions to the field of inventions underscore his position as a pioneering inventor. His work not only transforms the landscape of technology but also serves as a testament to the power of creativity and perseverance in the pursuit of scientific excellence.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…